RFM Stock Chart & Stats
€0.24
<€0.01(3.18%)
At close: 4:00 PM EDT
€0.24
<€0.01(3.18%)
Day’s Range― - ―
52-Week Range€0.19 - €32.50
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€5.61B
Enterprise Value€55.00
Total Cash (Recent Filing)€47.46M
Total Debt (Recent Filing)€1.28M
Price to Earnings (P/E)―
Beta0.92
Next Earnings
Sep 23, 2026EPS Estimate
-1.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding10,312,972
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.49
Price to Book (P/B)2.28
Price to Sales (P/S)0.00
P/FCF Ratio-3.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€1.00Price Target Upside316.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.63
Revenue Forecast (FY)€18.88M
Bulls Say, Bears Say
Bulls Say
Low LeverageLow leverage provides greater financial flexibility than a heavily indebted balance sheet would, allowing more cash to be directed toward research and development. It also reduces near-term interest and refinancing pressure while the company advances its clinical programs.
Prior Revenue ExpansionThe multi-year revenue increase through 2024 demonstrates that Sensorion has previously generated expanding collaboration or licensing-related income. That history supports the possibility of rebuilding partnership revenue as development programs progress, despite the subsequent 2025 disruption.
Focused Development PipelineA focused pipeline in inner-ear diseases gives Sensorion a clear therapeutic specialization rather than a broad, unfocused research agenda. Multiple development approaches, including gene therapy, can create several routes to clinical progress and future partnering opportunities.
Bears Say
Revenue DisruptionThe move to zero annual revenue represents a major break from the prior growth trajectory and leaves the company without established operating revenue. This increases dependence on partnerships, grants, or financing and makes future funding capacity more central to program execution.
Persistent Cash BurnDeeply negative operating and free cash flow show that the current business does not fund its own research activities. Continued cash consumption can shorten the runway and require repeated external funding, potentially constraining development priorities or increasing financing dependence.
Ongoing Losses And Equity PressureLarge operating and net losses are reducing the company’s equity base despite low debt, while returns remain consistently negative. If this pattern continues, Sensorion may need additional capital to sustain development, raising the risk of dilution and limiting financial resilience.
Sensorion SAS News
RFM FAQ
What was Sensorion SAS’s price range in the past 12 months?
Sensorion SAS lowest stock price was €0.19 and its highest was €32.50 in the past 12 months.
What is Sensorion SAS’s market cap?
Sensorion SAS’s market cap is €5.61B.
When is Sensorion SAS’s upcoming earnings report date?
Sensorion SAS’s upcoming earnings report date is Sep 23, 2026 which is in 6 days.
How were Sensorion SAS’s earnings last quarter?
Sensorion SAS released its earnings results on Mar 18, 2026. The company reported -€2 earnings per share for the quarter, beating the consensus estimate of -€3 by €1.
Is Sensorion SAS overvalued?
According to Wall Street analysts Sensorion SAS’s price is currently Undervalued.
Does Sensorion SAS pay dividends?
Sensorion SAS does not currently pay dividends.
What is Sensorion SAS’s EPS estimate?
Sensorion SAS’s EPS estimate is -1.39.
How many shares outstanding does Sensorion SAS have?
Sensorion SAS has 10,312,972 shares outstanding.
What happened to Sensorion SAS’s price movement after its last earnings report?
Sensorion SAS reported an EPS of -€2 in its last earnings report, beating expectations of -€3. Following the earnings report the stock price went down -2.154%.
Which hedge fund is a major shareholder of Sensorion SAS?
Currently, no hedge funds are holding shares in DE:RFM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sensorion SAS
Sensorion SA is a clinical-stage biopharmaceutical firm based in Montpellier, France, specializing in the development of therapies for inner ear disorders. Their key initiatives include gene therapy programs: OTOF-GT, designed to restore hearing for individuals with Otoferlin deficiency, and USHER-T1-GT, targeting Usher syndrome Type 1. The company also advances SENS-401, a drug candidate for treating sudden sensorineural hearing loss. Sensorion's broader pipeline encompasses numerous experimental treatments aimed at restoring, treating, and preventing various conditions affecting the inner ear. They hold a collaboration agreement with Institut Pasteur concerning gene therapy for both pediatric and adult deafness. Additionally, Sensorion partners with Sonova Holding AG to integrate genetic analysis into the routine diagnosis of progressive adult hearing loss, combining advanced therapeutic approaches with traditional hearing aids. Founded in 2009, Sensorion SA operates primarily in France.
RFM Stock 12 Month Forecast
Average Price Target
€1.00
▲(316.67% Upside)